Ignite Creation Date:
2025-12-25 @ 12:19 AM
Ignite Modification Date:
2026-02-28 @ 2:28 PM
Study NCT ID:
NCT00615758
Status:
COMPLETED
Last Update Posted:
2009-12-15
First Post:
2008-02-01
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Erlotinib as 1st Line Treatment in NSCLC Stage IIIB/IV
Sponsor:
Hellenic Oncology Research Group
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
CT/06.03
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
None
Responsible Party Affiliation:
Old Name:
V.Georgoulias
Old Organization:
Hellenic Oncology Research Group
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | OTHER | View |